As stated in the Master Activity Plan, GTB has set the growth indicators (KPIs) to visualize the results of its activities. The prime KPI is the total sales of member companies of the five biotechnology-related organizations in the GTB area (listed companies and non-listed companies for which sales figures are available; hereinafter referred to as “member companies”), with the goal of expanding total sales from 102 trillion yen in FY2020 to 145 trillion yen by 2030 through annual growth of 3.6% (*The current status and target figures have been slightly revised due to the recalculation.).
Here, we are pleased to announce that we have calculated the figures as of FY2021.
The total sales of member companies in FY2021 are 135 trillion yen, a 33% increase over FY2020. This increase is largely due to the sales added by new member companies of the five biotech-related organizations, but a comparison of 166 existing member companies whose sales in FY2020 and FY2021 can be compared shows an increase of about 10.2 trillion yen in sales over FY2020, corresponding to a 10.8% growth.
Detailed data were shown in the attached file.